이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Morphic Holding 배당금

배당금 기준 확인 0/6

Morphic Holding 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	2.8%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$3.22
3년 후 배당 수익률 예측	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Jun 26

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Jan 20

Companies Like Morphic Holding (NASDAQ:MORF) Are In A Position To Invest In Growth

Sep 29

We're Interested To See How Morphic Holding (NASDAQ:MORF) Uses Its Cash Hoard To Grow

Jun 07

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Feb 15

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Jan 03

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Nov 08

Morphic GAAP EPS of -$0.68 beats by $0.17, revenue of $60.2M

Aug 03

Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF)

May 06

Analyst Forecasts Just Became More Bearish On Morphic Holding, Inc. (NASDAQ:MORF)

Mar 01

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Feb 17

Independent Director Vikas Goyal Just Bought A Handful Of Shares In Morphic Holding, Inc. (NASDAQ:MORF)

Mar 09

Did Business Growth Power Morphic Holding's (NASDAQ:MORF) Share Price Gain of 126%?

Feb 24

How Many Morphic Holding, Inc. (NASDAQ:MORF) Shares Have Insiders Sold, In The Last Year?

Jan 20

Morphic Holding (MORF) Presents At 39th Annual Healthcare Conference - Slideshow

Jan 14

Companies Like Morphic Holding (NASDAQ:MORF) Can Afford To Invest In Growth

Dec 16

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 MORF 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: MORF 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Morphic Holding 시장 대비 배당 수익률

MORF 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (MORF)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Biotechs)	2.8%
3년 후 애널리스트 예측 (MORF)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 MORF 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 MORF 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 MORF 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: MORF 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Morphic Holding 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Morphic Holding, Inc., Annual General Meeting, Jun 04, 2024

Morphic Therapeutic Appoints Simon Cooper as Chief Medical Officer

Consensus revenue estimates decrease by 88%, EPS upgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Key Executive exercised options and sold US$174k worth of stock

Insufficient new directors

Price target decreased by 10% to US$55.13

Consensus EPS estimates upgraded to US$3.41 loss

Morphic Holding, Inc. Announces Chief Executive Officer Changes

Third quarter 2023 earnings released: US$0.73 loss per share (vs US$0.78 loss in 3Q 2022)

Companies Like Morphic Holding (NASDAQ:MORF) Are In A Position To Invest In Growth

Price target decreased by 13% to US$65.38

Morphic Holdings Inc. Announces Chief Executive Officer, Praveen Tipirneni Suffered an Emergent Medical Event and Taking Medical Leave of Absence

CFO & COO notifies of intention to sell stock

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$0.70 profit in 2Q 2022)

CEO, MD & Director exercised options and sold US$190k worth of stock

We're Interested To See How Morphic Holding (NASDAQ:MORF) Uses Its Cash Hoard To Grow

General Counsel & Secretary notifies of intention to sell stock

Price target increased by 14% to US$73.88

Price target increased by 14% to US$73.88

First quarter 2023 earnings: EPS and revenues miss analyst expectations

CFO & COO exercised options to buy US$279k worth of stock.

CFO & COO notifies of intention to sell stock

Consensus revenue estimates decrease by 29%, EPS upgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President exercised options and sold US$358k worth of stock

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Morphic Holding, Inc. announced that it expects to receive $29.999954 million in funding

CEO, MD & Director exercised options and sold US$123k worth of stock

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Morphic Therapeutic AnnouncesInitiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022

Consensus revenue estimates increase by 437%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Morphic GAAP EPS of -$0.68 beats by $0.17, revenue of $60.2M

Price target decreased to US$66.43

Morphic Therapeutic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

Morphic Holding, Inc. Announces Management Appointments

Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Morphic Holding, Inc., Annual General Meeting, Jun 08, 2022

Price target decreased to US$74.50

Morphic Therapeutic Announces Management Appointments

Chief Scientific Officer exercised options and sold US$367k worth of stock

Consensus revenue estimates fall by 38%

Analyst Forecasts Just Became More Bearish On Morphic Holding, Inc. (NASDAQ:MORF)

Price target decreased to US$75.80

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Morphic Holding, Inc. Announces Retirement of Dr. Nilesh Kumar from the Board and Resign as Member of the Board and the Audit and Nominating and Governance Committees

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Price target decreased to US$83.80

General Counsel & Secretary exercised options to buy US$827k worth of stock.

Price target decreased to US$95.00

Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.17 profit in 3Q 2020)

CFO & COO exercised options and sold US$246k worth of stock

We're Not Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn

CFO & COO exercised options and sold US$1.3m worth of stock

Morphic: Pioneering Integrin Medicines

Chief Scientific Officer notifies of intention to sell stock

Founder recently bought US$4.2m worth of stock

Consensus EPS estimates fall to -US$2.73

Second quarter 2021 earnings released: US$0.77 loss per share (vs US$0.52 loss in 2Q 2020)

Morphic Holding (NASDAQ:MORF) Is In A Strong Position To Grow Its Business

Morphic Holding, Inc.(NasdaqGM:MORF) dropped from Russell 3000E Index

Insider notifies of intention to sell stock

Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 At ECCO'21 Virtual Congress

Founder recently bought US$11m worth of stock

Consensus forecasts updated

Independent Director has left the company

First quarter 2021 earnings released: US$0.64 loss per share (vs US$0.56 loss in 1Q 2020)